Landscapes / Companies
Swedish Orphan Biovitrum not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
Drugs
5
in active trials · 10 in all
Trials
9 active
33 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Kinase inhibitor |
CTI BioPharma |
Approved | 30 Dec 2026Phase 2 trial completes | ||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis and 3 more | ||||
| Open drug page | |||||
— |
Approved in the EU | 15 Jan 2027Phase 3 trial completes | |||
| Next date | 15 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Hemophilia A, Haemophilia A (Moderate or Severe) and 6 more | ||||
| Open drug page | |||||
— |
Approved | 30 Jun 2028Phase 2/3 trial completes | |||
| Next date | 30 Jun 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Aplastic Anemia | ||||
| Open drug page | |||||
Complement inhibitor |
Apellis Pharmaceuticals |
Approved | 17 Jan 2031Phase 3 trial completes | ||
| How it works | Blocks part of the complement system | ||||
| Next date | 17 Jan 2031 · Phase 3 trial completes | ||||
| Also tested for | C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and 2 more | ||||
| Open drug page | |||||
Interleukin-1 receptor antagonist |
Approved | — | |||
| Also tested for | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | ||||
| Open drug page | |||||
About
- No active trial
- NI-0501, Nitisinone, Recombinant coagulation factor, SEL-212, SOBI003
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021